2018
DOI: 10.1159/000488713
|View full text |Cite
|
Sign up to set email alerts
|

Prazosin but Not Tamsulosin Sensitises PC-3 and LNCaP Prostate Cancer Cells to Docetaxel

Abstract: Background/Aims: Docetaxel is currently the first-line chemotherapeutic agent available for the treatment of patients with advanced prostate cancer (PCa). While docetaxel has been shown to modestly improve survival times for patients; they also experience significant docetaxel-induced toxicities. If treatment failure occurs, there are currently limited alternatives that show survival benefits for patients and therefore there is an urgent need for adjunct therapies. Some quinazoline-based alpha1-adrenoceptor (A… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
7
0

Year Published

2018
2018
2022
2022

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 8 publications
(7 citation statements)
references
References 28 publications
0
7
0
Order By: Relevance
“…In normal physiological conditions, ROS are natural by-products of aerobic respiration and metabolism. Some anticancer agents, such as gemcitabine (35), pemetrexed (36), gefitinib (37), paclitaxel (38, 39), vinorelbine (40), docetaxel (41), CBP (42), and oxaliplatin (43), work by generating ROS. The overaccumulation of ROS induces cell apoptosis through internal and external apoptotic pathways (44).…”
Section: Discussionmentioning
confidence: 99%
“…In normal physiological conditions, ROS are natural by-products of aerobic respiration and metabolism. Some anticancer agents, such as gemcitabine (35), pemetrexed (36), gefitinib (37), paclitaxel (38, 39), vinorelbine (40), docetaxel (41), CBP (42), and oxaliplatin (43), work by generating ROS. The overaccumulation of ROS induces cell apoptosis through internal and external apoptotic pathways (44).…”
Section: Discussionmentioning
confidence: 99%
“…This hypothesis is supported by the findings of Lin et al that PRZ induces DNA damage stress in PC-3 prostate cancer cells [49]. Furthermore, Spencer et al have demonstrated recently that PRZ sensitises prostate cancer cells to docetaxel [66]. The latter is a chemotherapeutic agent which targets microtubules and induces cell death in cancer cells through induction of Mitotic Catastrophe [67].…”
Section: Discussionmentioning
confidence: 72%
“…Therefore, blocking tumor metastasis and invasion is a necessary strategy for osteosarcoma therapy. It has been well-documented that Prazosin enhances the apoptosis rate in a number of tumor cells, displaying anti-growth activity in prostate cancer ( 12 , 13 , 15 ), glioblastoma ( 16 ), and MTC cells ( 9 ). In the present study, we have tested and identified Prazosin as a novel anti-cancer agent in osteosarcoma cells.…”
Section: Discussionmentioning
confidence: 99%
“…Similarly, Fuchs et al confirm that Prazosin treatment inhibits the growth of medullary thyroid carcinoma (MTC) cells, also inducing apoptosis ( 9 ). Further studies have also revealed that Prazosin reduces cell proliferation and increases docetaxel-induced toxicity in prostate cancer cells, by modulating autophagy and apoptosis ( 13 ).…”
Section: Introductionmentioning
confidence: 99%